Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
6
55%
Ph not_applicable
3
27%
Ph phase_2
2
18%

Phase Distribution

0

Early Stage

2

Mid Stage

6

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
2(18.2%)
Phase 4Post-market surveillance
6(54.5%)
N/ANon-phased studies
3(27.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(3)
Other(8)

Detailed Status

unknown8
Completed3

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (18.2%)
Phase 46 (54.5%)
N/A3 (27.3%)

Trials by Status

completed327%
unknown873%

Recent Activity

0 active trials
Showing 5 of 11
unknownphase_4

Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells

NCT06026995
completedphase_2

Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer

NCT04542356
unknownnot_applicable

the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma

NCT05834751
unknownphase_2

Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma

NCT04460508
unknownnot_applicable

PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation

NCT05156554
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT06026995Phase 4

Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells

Unknown
NCT04542356Phase 2

Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer

Completed
NCT05834751Not Applicable

the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma

Unknown
NCT04460508Phase 2

Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma

Unknown
NCT05156554Not Applicable

PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation

Unknown
NCT04500886Not Applicable

Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome

Unknown
NCT04083079Phase 4

Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma

Unknown
NCT03206684Phase 4

To Evaluate the Efficacy and Safety of PEG-rhG-CSF（Jinyouli®） in Reducing Neutropenia in Patients With Cervical Cancer

Unknown
NCT02905942Phase 4

PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation

Unknown
NCT02805153Phase 4

PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy

Completed
NCT01479114Phase 4

Effect of Recombinant Human Granulocyte Colony- Stimulating Factor on CD11b in Septic Neonates

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11